BEIJING, China, August 17, 2026 -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited fi

BEIJING, China, August X, 2026 — SINOVAC announced that its Serum-Free Rabies Vaccine for Human Use has received a Drug Registration Certificate from China's National Medical Products Administrati

BEIJING, China, July 31, 2026 — A study evaluating the optimal timing of a booster dose of varicella vaccine among school-aged children has been published in the Chinese Journal of Epidemiology. The r

BEIJING, China, July 31, 2026 — SINOVAC announced that a large-scale prospective cohort study evaluating the effectiveness of itsvaricella vaccine, live has been published in the peer-reviewed journal

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has extended the dead

BEIJING, June 24, 2026 — SINOVAC and GENNVAX, Egyptian local partner, signed an agreement for the localized production of influenza and Sabin-strain inactivated poliovirus (sIPV) vaccines during the 5

Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading biopharmaceutical enterprise from China, recently hosted more than 100 public health and

BEIJING, China June 15, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it r

Beijing, China - Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, initiated enrollment for a Phase IIIa c

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form

BEIJING, China May 29, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it re

May 27, 2026 — SINOVAC has received approval from the National Medical Products Administration (NMPA) to launch clinical trials for its Influenza Vaccine (Split Virion), Inactivated (MDCK cell). The P

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has extended the dead

DHAKA, Bangladesh, May 13, 2026 — Sinovac Foundation, an affiliate of Sinovac Biotech Ltd. (SINOVAC), has donated 76,616 vials (383,080 doses) of the company’s Poliomyelitis Vaccine (Vero Cell), Inact

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months

BEIJING, April 30, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it filed

Yogyakarta, April 21, 2026 - SINOVAC and Indonesia's Universitas Gadjah Mada, signed a memorandum of understanding in Yogyakarta on April 21, 2026 to deepen R&D cooperation.

BEIJING, March 27, 2026 — Sinovac Holding Group (“SINOVAC”) and Bio Farma, Indonesia's state-owned pharmaceutical company, signed a strategic memorandum of understanding in Beijing on March 27, 20

BEIJING, January 27, 2026 – Co-administration of SINOVAC's Sabin-strain inactivated poliovirus vaccine (sIPV) with either measles-mumps-rubella (MMR) or inactivated hepatitis A (HepA) vaccines is

BEIJING, January 22, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (